HOUSTON--(BUSINESS WIRE)--PLx Pharma announced the award of a U.S. Army contract totaling $730,000 as part of the Army’s Small Business Innovation Research (SBIR) program. The award funds continued development of PL 4500, a molecular complex of indomethacin and phosphatidylcholine that is being developed as a GI safer anti-inflammatory and analgesic in both oral and IV formulations.
